Faecalibacterium prausnitzii in Differentiated Thyroid Cancer Patients Treated with Radioiodine

Data de publicação:

Autores da FMUP

  • Raquel Ângela Silva Soares Lino

    Autor

Participantes de fora da FMUP

  • Fernandes, A
  • Oliveira, A
  • Carvalho, AL
  • Barata, P

Unidades de investigação

Abstract

Background: Faecalibacterium prausnitzii, one of the most important bacteria of the human gut microbiota, produces butyrate (a short-chain fatty acid). Short-chain fatty acids are known to influence thyroid physiology and thyroid cancer's response to treatment. We aimed to analyze the relative abundance of Faecalibacterium prausnitzii on the gut microbiota of differentiated thyroid cancer patients compared to controls and its variation after radioiodine therapy (RAIT). Methods: Fecal samples were collected from 37 patients diagnosed with differentiated thyroid cancer before and after radioiodine therapy and from 10 volunteers. The abundance of F. prausnitzii was determined using shotgun metagenomics. Results: Our study found that the relative abundance of F. prausnitzii is significantly reduced in thyroid cancer patients compared to volunteers. We also found that there was a mixed response to RAIT, with an increase in the relative and absolute abundances of this bacterium in most patients. Conclusions: Our study confirms that thyroid cancer patients present a dysbiotic gut microbiota, with a reduction in F. prausnitzii's relative abundance. In our study, radioiodine did not negatively affect F. prausnitzii, quite the opposite, suggesting that this bacterium might play a role in resolving radiation aggression issues.

Dados da publicação

ISSN/ISSNe:
2072-6643, 2072-6643

Nutrients  Multidisciplinary Digital Publishing Institute (MDPI)

Tipo:
Article
Páginas:
2680-
Link para outro recurso:
www.scopus.com

Citações Recebidas na Scopus: 5

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • Faecalibacterium prausnitzii; thyroid cancer; radioiodine therapy; gut microbiota; metagenomic sequencing

Proyectos asociados

Effects of Xanthohumol on Metabolic Syndrome Progression (XAN4Health) - NCT03561116

Investigador Principal: Raquel Ângela Silva Soares Lino

Ensaio Clínico Académico (XAN4Health) . TA XAN . 2019

SARS-CoV-2 e Angiogénese: uma ligação por explicar

Investigador Principal: Raquel Ângela Silva Soares Lino

Estudo Clínico Académico . 2021

The use of targeted angiogenic therapies for ischemic diabetic foot ulcer repair.

Investigador Principal: Raquel Ângela Silva Soares Lino

Estudo Clínico Académico . 2022

Citar a publicação

Partilhar a publicação